Navigation Links
ERT Launches New Website to Support Significant Commercial Growth
Date:2/15/2012

PHILADELPHIA, Feb. 15, 2012 /PRNewswire/ -- ERT (NASDAQ: ERT), a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announced today the launch of a new corporate website to further elevate its market and thought leadership position. Complementing the company's commercial growth in the last 18 months, web traffic to ERT's website increased by 41% from June 2010 to October 2011, as visitors sought further detailed information about ERT's comprehensive range of Cardiac Safety, Respiratory and ePRO solutions. To access the new website, visit www.ert.com.

The newly created website has been designed to reflect ERT's position as a company offering unrivaled processes and scientific expertise to collect, analyze and report on clinical data. This is done in order to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products.

Created to provide a new online customer experience, the website provides enhanced content and improved navigation in order to give visitors a more comprehensive and in-depth understanding of ERT's services and expertise in the health outcomes research field. Providing in-depth information on ERT's distinctive cardiac safety, respiratory and ePRO solutions, visitors are also able to learn about ERT's clinical consulting services, which offer essential scientific and regulatory expertise in order to ensure quality trial data.

ERT's commitment to making valuable resources available to patients and clients is fully realized by the new website. Leveraging the research of ERT's experts and other thought leaders, the site offers a resource center that provides continually updated links to articles, white papers and webinars, in addit
'/>"/>

SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hooper Holmes Heritage Labs Division Launches New Home Diabetes Test
2. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
3. StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress
4. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
5. ETEX Launches Innovative Osteoinductive Orthobiologic, EquivaBone(TM)
6. ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration
7. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
8. Peakdale Molecular Launches AssayReady4U(TM) in Collaboration With ChemPrintCo LLC
9. BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices
10. SearchMedica Launches Practice Management Search Engine for Medical Professionals
11. Familybuilder Launches the Familybuilder Global Network at DEMOfall 08
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)...  Kerastem Technologies announce that the Company has received ... For Biologics Evaluation and Research (CBER) Office of Cellular, ... investigating the safety and feasibility of the Company,s technology ... baldness (androgenic alopecia). The phase II study, ... in Europe and ...
(Date:7/28/2015)... , July 28, 2015 CSL ... Drug Administration has accepted for review the company,s Biologics ... VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. ... endpoints. Hemophilia A is ... factor VIII; nearly all affected patients are male. People ...
(Date:7/28/2015)... Israel , July 28, 2015 ... medicine company utilizing its proprietary plant-based rhCollagen technology ... Shurtz has been appointed Senior Director of Business ... (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... in marketing, regulatory and business strategy. Prior to ...
(Date:7/27/2015)... CHICAGO and FRANKLIN, Tenn. ... Inc. ("Capella"), a privately-owned  premier provider of health care ... companies in the U.S., today announced that its ... has signed a definitive agreement with Medical Properties ... the acquisition of Capella for $900 million in cash.  The ...
Breaking Biology Technology:Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 2Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 3Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 4Capella Healthcare Announces Agreement With Medical Properties Trust, Inc. 5
... May 17, 2011 Amgen (NASDAQ: AMGN ... 3 trial (,147) demonstrating that XGEVA™ (denosumab) significantly increased ... men with castrate-resistant metastatic prostate cancer that has not ... study were presented for the first time today in ...
... DIEGO, May 17, 2011 P ... that it has submitted a Biologics Master File (BMF) to ... grade CRM197 carrier protein to support the development of conjugate ... Proteins is supplying cGMP grade CRM197 carrier protein to multiple ...
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... "Company"), a developer, manufacturer and distributor of botanical ... China, today announced that the Company successfully showcased ... ("the fair") recently held in Chengdu, China. ...
Cached Biology Technology:Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 2Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 3Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 4Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 5Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 6Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 7Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 8Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 9Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 2China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 3
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... -- This report provides market analysis of the Automatic ... contains an analysis of the drivers, challenges, and restraints ... the short, medium, and long term perspective landscapes. ... technology trends that currently, prevail in the market. It ... efficiently manage the increasing marine traffic and increasing importance ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... A thin polymer bio-film that seals surgical wounds could make ... thick, the film is placed on a surgical wound and ... enough to meld it and the tissue, thus perfectly sealing ... is extracted from crab shells and has Food and Drug ...
... greenhouse gas, is emitted in great quantities as bubbles from ... of these bubbles dissolve into the ocean, but the fate ... of California, Santa Barbara have discovered that only one percent ... news for the Earth,s atmosphere. Coal Oil Point (COP), ...
... Center for Ecological Analysis and Synthesis have developed a ... across landscapes. Their approach could give managers a better ... which are crucial to protecting biodiversity. There are ... connectivity, said Brad McRae, head of the project. Its ...
Cached Biology News:Surgery without stitches 2Scientists find good news about methane bubbling up from the ocean floor 2Model connects circuit theory to wildlife corridors 2
... antibody raised against a partial recombinant IFNA2. ... partial recombinant protein is produced in E. coli. ... IU/ mg. OMIM: 147562, ... Lot Number: MM951100564 MA Code: ...
... V, is used to coat the inner wall ... the source of the DNA that enters target ... gun. The station includes a tubing support cylinder, ... Nalgene nitrogen regulator hose, two 0.1875 inch barb-to-male ...
... Microarray Hybridization Wash Pack provides ... microarray slides. Preparation Quality Clarifier: Ready-to-use ... use with SigmaScreen(tm) APS Coated Slides ... Microarray Hybridization Blocking Buffer: 1L ...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
Biology Products: